Abstract: Gefitinib (ZD1839) is a pioneering first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has significantly transformed the therapeutic landscape for non-small cell lung cancer (NSCLC). Despite its potent pharmacological activity and defined molecular mechanism targeting the ATP-binding cleft of EGFR, its long-term clinical utility is hindered by acquired resistance, severe toxicities such as interstitial lung disease, and poor central nervous system penetration. To address these challenges, recent research has pivoted toward novel drug delivery systems. Advanced nanomedicine strategies, particularly the co-delivery of small-molecular drugs with nucleic acids (e.g., siRNAs and miRNAs), offer a promising paradigm to overcome multidrug resistance, synchronize pharmacokinetics, and enhance targeted anticancer efficacy.
1. Introduction
Lung cancer remains a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) comprising approximately 85% of all cases [1]. Historically, advanced NSCLC was treated with platinum-based chemotherapy, which offered limited survival benefits and a median overall survival of only 10 to 12 months [1]. The discovery of the epidermal growth factor receptor (EGFR) as a critical therapeutic target revolutionized oncological treatment. In 1997, gefitinib (ZD1839), developed by AstraZeneca, was selected for clinical development as the first EGFR-TKI [1]. It marked a milestone in targeted therapy, providing significant survival benefits and improved quality of life for NSCLC patients, particularly those harboring specific somatic EGFR-activating mutations such as exon 19 deletions or the L858R point mutation in exon 21 [4][5].
2. Pharmacological Activity
Gefitinib exhibits potent anti-tumor activity by effectively inhibiting the downstream signaling pathways of EGFR. It induces cell cycle arrest by upregulating p27KIP1, which leads to G1 arrest, and suppresses tumor angiogenesis in a dose-dependent and reversible manner [1]. Pivotal clinical trials, such as the IDEAL studies and the Iressa Pan-Asia Study (IPASS), demonstrated that gefitinib provides superior progression-free survival (PFS) and higher objective response rates (ORR) compared to standard carboplatin and paclitaxel chemotherapy in selected patient populations [1]. Despite its systemic efficacy, gefitinib's pharmacological reach into the central nervous system (CNS) is highly restricted. It exhibits a low cerebrospinal fluid (CSF) penetration rate of approximately 1.13% and achieves a minimal CNS concentration of only 3.7 ng/mL, which limits its effectiveness against brain and leptomeningeal metastases [5].
3. Molecular Mechanism of Action
Under physiological conditions, the binding of ligands (such as EGF) to the extracellular domain of EGFR induces receptor dimerization and subsequent autophosphorylation of its intracellular tyrosine kinase domain. This activation triggers a cascade of downstream intracellular signaling pathways, including MAPK, AKT, JNK, and PI3K/AKT, which are responsible for DNA synthesis, cell proliferation, and survival [5][6]. Gefitinib functions as a competitive inhibitor that reversibly binds to the ATP-binding cleft within the tyrosine kinase domain of EGFR. By occupying this site, gefitinib blocks the transmission of the activation signal to the cell interior, thereby inhibiting continuous receptor stimulation, halting tumor cell proliferation, stimulating apoptosis, and reducing invasiveness and angiogenesis [5].
4. Structure-Activity Relationship (SAR)
Structurally, gefitinib is a 4-anilinoquinazoline compound [5]. Its inhibitory efficacy is heavily dependent on its ability to fit precisely into the ATP cleft of the EGFR tyrosine kinase domain. Within this pocket, gefitinib forms critical hydrogen bonds with specific amino acid residues, most notably methionine 769 (M769) [5]. The presence of activating mutations in the EGFR gene alters the spatial conformation of the kinase domain, which significantly increases the receptor's affinity for the inhibitor compared to wild-type EGFR, explaining the heightened clinical response in mutation-positive patients [5]. Conversely, structural alterations in this binding pocket due to secondary mutations can sterically hinder gefitinib from binding, leading to a loss of pharmacological activity.
5. Current Limitations
The long-term clinical success of gefitinib is compromised by several significant limitations:
Acquired Resistance: Despite initial dramatic responses, acquired resistance to gefitinib is inevitable. The most common mechanism is the emergence of the T790M gatekeeper mutation in exon 20 of the EGFR gene, which alters the ATP-binding pocket and prevents the drug from binding effectively [5][7]. Other resistance mechanisms include MET amplification, histologic transformation, and the compensatory activation of alternative signaling pathways (e.g., PI3K/Akt or Ras/ERK) [1][6].
Toxicity and Adverse Events: Gefitinib is associated with notable toxicities. Common adverse events include diarrhea (affecting 34–61% of patients) and elevated liver transaminases (25–55%) [4]. More severely, gefitinib can induce fatal interstitial lung disease (ILD). Although ILD occurs at a low frequency (1.1–2.2%), it accounts for 58% of all EGFR-TKI treatment-related deaths [4]. Additionally, nephrotoxicity and acute kidney injury have been documented as complications during targeted oncological treatments [3].
Poor CNS Penetration: As previously noted, the low molecular weight of gefitinib does not translate to effective blood-brain barrier penetration, leaving the CNS as a frequent sanctuary site for metastatic relapse [5].
6. Future Perspectives
To overcome the hurdles of multidrug resistance (MDR), systemic toxicity, and poor bioavailability, current research is heavily focused on the development of novel drug delivery systems [2]. Nanomedicine provides advanced platforms—such as liposomes, polymeric micelles, mesoporous silica nanoparticles, and functionalized magnetic graphene—to improve the pharmacokinetic profiles and targeted distribution of small-molecular drugs like gefitinib [2].
A highly promising frontier is the co-delivery of chemotherapeutics with nucleic acid drugs (e.g., siRNA, miRNA, pDNA) to synergistically target multiple dysregulated cellular pathways [2]. Preclinical evidence shows that combining EGFR-TKIs with specific microRNAs can reverse acquired resistance. For example, the overexpression of miR-133a-3p, miR-483-3p, or miR-34a has been shown to suppress epithelial-mesenchymal transition (EMT), promote apoptosis, and re-sensitize resistant NSCLC cells to gefitinib [6].
Advanced delivery strategies are broadly categorized into two types: "1+1" sequential delivery systems, which utilize separate nanocarriers to optimize the timing of drug action (e.g., sensitizing the tumor with a nucleic acid before releasing the small molecule), and "2 in 1" co-encapsulation systems, which load both agents into a single carrier [2]. The "2 in 1" approach ensures synchronized pharmacokinetics and allows for the delivery of controllable relative amounts of both agents directly to the target cells [2]. Furthermore, the development of drug-carrier conjugates delivering drugs (DCDD), where small-molecular drugs are covalently inserted into the delivery materials, reduces premature drug leakage and enhances synergistic effects [2]. These multifunctional, targeted nanocarriers represent the future of precision oncology, aiming to maximize the therapeutic efficacy of compounds like gefitinib while minimizing adverse side effects.
